Venezuela Medical Device Recalls 2026: Field Corrective Action and Execution Limits

1. Key takeaways

In Venezuela, a recall or field corrective action is executed by the license holder or importer; a foreign manufacturer cannot carry it out directly. What the manufacturer can do is take the decision, provide resources and supply technical support. The market-facing action has to be performed by the local entity.

The conclusion is this: recall capability is in essence the capability of the license holder, not of the manufacturer. Screening for recall execution capability when selecting an authorized representative and license holder matters more than designing a recall process after the product is on the market, because the second depends entirely on the first. A recall procedure written to a high standard is only a description of what someone else must be able to do.

The practical corollary is that recall readiness is a selection criterion with a long lead time. Changing a license holder is not a step taken in the middle of a recall; it is a decision made years earlier, on the basis of distributor control, hospital relationships and record-keeping discipline rather than on price.

2. Legal basis

Position statement: the specific reporting requirements, classification and deadlines for recalls were not traced in this verification to a Venezuelan official instrument that can be cited directly, and are marked as a practical estimate.

Article 67 of the medicines law supplies the operative prohibition: non-compliant products may not circulate. A recall is the mechanism through which a product that has become non-compliant is brought back out of circulation, which is why the obligation to remove it falls on the party that holds the registration and physically controls the goods. The circular adds the traceability requirement that makes removal possible in the first place, and the organic regulation places the function that monitors both inside SACS.

3. Expert insights

1. Every link in the execution chain can become the break point. The complete chain runs as follows: the manufacturer decides, notifies the license holder, the license holder notifies distributors, distributors notify health institutions, product is recovered, SACS is notified, and disposition and records are completed. If any link breaks, the recall cannot be closed out. And the manufacturer controls only the first link. This asymmetry is the reason recall planning has to be treated as an exercise in influencing parties outside the organization rather than as an internal quality procedure.

Two steps in that chain are habitually left undefined. The first is disposition: what physically happens to recovered stock, who authorizes destruction or return, and who pays for it. The second is the closing report: who compiles it, in what form, and to whom it is addressed. Neither question is answered by a global recall procedure, and both are decided at the moment when speed matters most. Settling them in the agreement, in advance and in writing, is the cheapest form of recall readiness available to a manufacturer.

2. The level of traceability determines whether a recall is feasible at all. Circular DGSACS-008/2026 emphasizes safeguarding traceability. For a manufacturer this means batch identification and distribution records must be planned at the design stage. If the product itself has no capacity to carry batch information, or if distribution records are not maintained downstream, the recall is technically impossible to perform, regardless of how quickly the decision is taken or how complete the notification materials are. Design decisions taken years before a recall determine its feasibility.

3. Recall of implantable devices is materially harder. An implant is already inside a patient, so a recall implies a medical decision, namely whether to explant, rather than a simple product return. Recalling this category requires collaboration with health institutions and clinical specialists, and the local resource requirement is far higher than for conventional devices (article 18 of this series). The notification timeline also has to allow for clinical judgement, because a recall letter that demands immediate action on an implanted device will be resisted by the clinicians who have to act on it.

4. Informal channels make complete recall impossible. The Venezuelan market includes informal distribution routes, and products entering through those routes do not appear in the license holder’s distribution records. A recall notice cannot reach their users. This is a limitation specific to the Venezuelan market and should be made explicit in the risk assessment rather than assumed away. A recall plan that assumes a closed distribution system will report a completion rate it cannot support, and that overstatement is itself a finding.

4. Practical recommendations

1. Manufacturers: make recall execution capability a specific screening item when selecting an authorized representative and license holder, covering distributor network control, prior recall drill experience and channels for communicating with health institutions.
2. R&D and quality teams: fix the batch identification scheme at the design stage and establish a distribution record system at the license holder.
3. Regulatory affairs leads: specify recall cooperation duties, execution deadlines and cost sharing in the license holder agreement.
4. Quality teams: run recall drills periodically after launch, at least one documented exercise per year, to test whether the chain is actually reachable.
5. Clinical affairs: for implantable products, establish advance communication with health institutions and clinical specialists as part of the recall contingency plan.

5. Verification checklist

• □ Recall execution capability of the license holder is included in selection criteria
• □ The batch identification scheme is fixed and a distribution record system is in place
• □ The agreement specifies recall cooperation duties, deadlines and cost sharing
• □ An annual recall drill mechanism has been established
• □ An advance communication mechanism with health institutions exists for implantable products

Regulatory information verified as of October 29, 2026

All conclusions published here defer to the current regulatory texts as issued by the competent authority, verified item by item before delivery.

— GRZAN Regulatory Team

GRZAN supports medical device and IVD manufacturers, importers and authorized representatives with registration and post-market compliance in Venezuela: dossier preparation and filing through the SACS and COMEX channels, license-holder coordination, technovigilance and adverse event workflows, recall and field corrective action planning, inspection readiness, and continuous monitoring of circulares and decrees. For tailored support on your Venezuela portfolio, contact the GRZAN regulatory team at info@grzanglobal.com.